阿托伐他汀联合卡维地洛治疗慢性心力衰竭的效果分析

Analysis of the Effect of atorvastatin combined with carvedilol in the treatment of chronic heart failure

目的 探讨阿托伐他汀联合卡维地洛治疗对心力衰竭患者血清TNF-α、IL-1β、SCr、BUN的影响。方法选取2018年9月—2020年9月本院收治的心力衰竭患者104例,分为两组(随机数字表法),对照组采用卡维地洛治疗,研究组采用阿托伐他汀联合卡维地洛治疗。结果 研究组有效率为92.3%,大于对照组的84.6%,差异有统计学意义(χ^(2)=5.333,P=0.036)。治疗后,研究组SCr、BUN小于对照组(t=15.218、P=0.036,t=12.255、P=0.047),研究组TNF-α、IL-1β小于对照组(t=13.475、P=0.036、t=15.170、P=0.034)。研究组安全性大于对照组(5.8%vs 23.1%,χ^(2)=6.023,P=0.037)。结论 在心力衰竭治疗中,阿托伐他汀联合卡维地洛治疗效果明显,值得应用。

Objective To investigate the effect of atorvastatin combined with carvedilol on serum tumor necrosis factor-α (TNF-α),interleukin-1β (IL-1β),creatinine (Cr),and blood urea nitrogen (BUN) in patients with heart failure.Methods A total of 104 patients with heart failure treated in our hospital from September 2018 to September 2020 were divided into two groups by a random number table method.The control group was treated with carvedilol and the trial group was treated with atorvastatin combined with carvedilol.ResultsThe effective rate of the trial group was 92.3%,which was significantly higher than that of the control group (84.6%)(χ^(2)=5.333,P=0.036).After the treatment,serum Cr and BUN in the trial group were less than those in the control group,and the difference was statistically significant (t=15.218,P=0.036,t=12.255,P=0.047);serum TNF-α and IL-1β in the trial group were less than those in the control group,and the difference was statistically significant (t=13.475,P=0.036,t=15.170,P=0.034).The safety of the trial group was greater than that of the control group,and the difference was statistically significant (5.8%vs.23.1%,χ^(2)=6.023,P=0.037).Conclusion In the treatment of heart failure,atorvastatin combined with carvedilol is effective and worthy of application.